ADORA2A and cancer: Off-targetside effects of allosteric ligands are also expected to be lowered,as allosteric pockets are postulated to be less conserved with respectto the orthosteric binding site, and hence it should be possible toachieve higher receptor selectivity.5 EfficaciousNAMs of A2AR, scantly reported so far, have then the potentialof provide a safer, efficacious therapy option for cancer immunotherapyon high-adenosine TME.6